222 related articles for article (PubMed ID: 12869395)
1. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
Armstrong WB; Taylor TH; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
[No Abstract] [Full Text] [Related]
2. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
Kelloff GJ; O'Shaughnessy JA; Gordon GB; Hawk ET; Sigman CC
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):593-6. PubMed ID: 12869396
[No Abstract] [Full Text] [Related]
3. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
4. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
5. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers and surrogacy: relevance to chemoprevention.
Kensler TW; Davidson NE; Groopman JD; Muñoz A
IARC Sci Publ; 2001; 154():27-47. PubMed ID: 11220666
[TBL] [Abstract][Full Text] [Related]
7. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
Sanner T; Dybing E
Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
[TBL] [Abstract][Full Text] [Related]
8. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
9. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
Einspahr JG; Alberts DS; Gapstur SM; Bostick RM; Emerson SS; Gerner EW
Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):37-48. PubMed ID: 8993796
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
11. A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer.
Bogoch S; Bogoch ES
J Cell Biochem Suppl; 1994; 19():173-85. PubMed ID: 7823589
[TBL] [Abstract][Full Text] [Related]
12. Increasing the power of surrogate endpoint biomarkers: the aggregation of predictive factors.
Burke HB
J Cell Biochem Suppl; 1994; 19():278-82. PubMed ID: 7823601
[TBL] [Abstract][Full Text] [Related]
13. Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis.
Mori H; Yamada Y; Kuno T; Hirose Y
Mutat Res; 2004 May; 566(3):191-208. PubMed ID: 15082237
[TBL] [Abstract][Full Text] [Related]
14. The convergent development of molecular-targeted drugs for cancer treatment and prevention.
Lippman SM; Heymach JV
Clin Cancer Res; 2007 Jul; 13(14):4035-41. PubMed ID: 17634526
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention clinical trials: it is time to turn success into progress.
Brown PH
Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1531-2. PubMed ID: 17684123
[No Abstract] [Full Text] [Related]
16. Biomarker end-points in cancer chemoprevention trials.
Boone CW; Kelloff GJ
IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
[TBL] [Abstract][Full Text] [Related]
17. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
[TBL] [Abstract][Full Text] [Related]
18. Purified and endogenous phytic acid in wheat bran affects early biomarkers of colon cancer risk.
Jenab M; Thompson LU
IARC Sci Publ; 2002; 156():387-9. PubMed ID: 12484214
[No Abstract] [Full Text] [Related]
19. [Chemoprevention of (pre)malignant disorders of the head and neck area. Current situation].
de Vries N; Snow GB
Ned Tijdschr Tandheelkd; 1994 Mar; 101(3):93-4; quiz 95, 110. PubMed ID: 11830958
[TBL] [Abstract][Full Text] [Related]
20. Determination of biomarkers for intermediate end points in chemoprevention trials.
Lee JS; Lippman SM; Hong WK; Ro JY; Kim SY; Lotan R; Hittelman WN
Cancer Res; 1992 May; 52(9 Suppl):2707s-2710s. PubMed ID: 1348662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]